LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Listă Acțiuni・Gossamer Bio Inc

Gossamer Bio Inc

Închisă

SectorSănătate

0.33

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

0.32

Maxim

0.34

Indicatori cheie
By Trading Economics
Venit	983K -47M
Vânzări	505K 14M
Marjă de profit	-342.329
Angajați	161
EBITDA	-346K -46M

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	+1261.76% upside

Dividende
By Dow Jones
Următoarele câștiguri	18 mai 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-26M 79M
Deschiderea anterioară	0.33
Închiderea anterioară	0.33

Sentimentul știrilor

By Acuity

69%

31%

296 / 345 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

1.06 / 1.23 Suport & Rezistență

Gossamer Bio Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

17 mai 2026, 23:53 UTC

Achiziții, Fuziuni, Preluări

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15 mai 2026, 22:47 UTC

Acțiuni populare

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 mai 2026, 22:16 UTC

Achiziții, Fuziuni, Preluări

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 mai 2026, 22:00 UTC

Principalele dinamici ale pieței

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 mai 2026, 18:09 UTC

Principalele dinamici ale pieței

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17 mai 2026, 23:50 UTC

Market Talk

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17 mai 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

17 mai 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17 mai 2026, 23:36 UTC

Market Talk

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17 mai 2026, 23:07 UTC

Achiziții, Fuziuni, Preluări

UOB: Transactions Part of Group's Capital Reallocation Strategy

17 mai 2026, 23:06 UTC

Achiziții, Fuziuni, Preluări

UOB: Share Sale Agreements Entered With Singland Properties

17 mai 2026, 23:05 UTC

Achiziții, Fuziuni, Preluări

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17 mai 2026, 22:31 UTC

Achiziții, Fuziuni, Preluări

Prudential PLC to Fund Stake Acquisition via Internal Resources

17 mai 2026, 22:31 UTC

Achiziții, Fuziuni, Preluări

Prudential PLC to Acquire Stake for $389 Million

17 mai 2026, 22:30 UTC

Achiziții, Fuziuni, Preluări

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16 mai 2026, 16:27 UTC

Achiziții, Fuziuni, Preluări

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 mai 2026, 15:26 UTC

Achiziții, Fuziuni, Preluări

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16 mai 2026, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 mai 2026, 22:17 UTC

Achiziții, Fuziuni, Preluări

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mai 2026, 21:59 UTC

Achiziții, Fuziuni, Preluări

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 mai 2026, 21:50 UTC

Achiziții, Fuziuni, Preluări

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mai 2026, 21:30 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 mai 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 mai 2026, 20:19 UTC

Acțiuni populare

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 mai 2026, 19:41 UTC

Achiziții, Fuziuni, Preluări

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 mai 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 mai 2026, 18:35 UTC

Câștiguri

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Comparație

Modificare preț

Gossamer Bio Inc Așteptări

Obiectiv de preț

By TipRanks

1261.76% sus

Prognoză pe 12 luni

Medie 4.63 USD 1261.76%

Maxim 15 USD

Minim 0.3 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruGossamer Bio Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

8 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 8 analiști care au acordat evaluări ale acțiunilor Gossamer Bio Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

1.06 / 1.23Suport & Rezistență

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

296 / 345 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.